University of Cologne
uni-koeln.deTotal trials
199
Active
29
Phase 3
24
Total enrollment
232,786
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 23 of 23 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prednisone | — | — | — | — | 7 | ||
| Cyclophosphamide | — | — | — | — | 5 | ||
| Bleomycin | — | — | — | — | 5 | ||
| Brentuximab Vedotin | — | — | — | — | 4 | ||
| Vincristine | — | — | — | — | 4 | ||
| Doxorubicin | — | — | — | — | 4 | ||
| Etoposide | — | — | — | — | 4 | ||
| Procarbazine | — | — | — | — | 4 | ||
| Dexamethasone | — | — | — | — | 3 | ||
| Dacarbazine | — | — | — | — | 3 | ||
| Dapagliflozin 10 mg | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | 4 | ||
| Lenalidomide | — | — | — | — | 2 | ||
| Daratumumab | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Tislelizumab | — | — | — | — | — | 1 | |
| BrECADD | — | — | — | — | — | 1 | |
| Tafasitamab | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Pembrolizumab plus Chemotherapy | — | — | — | — | — | 1 | |
| Cablivi® | — | — | — | — | — | 1 |
Next readouts
- 2022-12
- 2025-03-15
- 2026-05
- 2026-05
- 2026-06
- 2026-09
- 2027-01
- 2027-02
- 2028-01
- 2030-05-15
Top conditions
- Hodgkin Lymphoma9
- Classical Hodgkin Lymphoma7
- Schizophrenia6
- Hyponatremia5
- Hodgkin´s Lymphoma4
- Glaucoma3
- Multiple Myeloma3
- Tic-Disorder3
Frequently asked questions about University of Cologne
- How many clinical trials does University of Cologne have on ClinicalTrials.gov?
- University of Cologne is listed as the lead sponsor on 199 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Cologne's trials are in Phase 3?
- 24 of University of Cologne's trials are in Phase 3, spread across 23 active drug programs.
- What therapeutic areas does University of Cologne focus on?
- University of Cologne's most-studied conditions on ClinicalTrials.gov are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Schizophrenia, Hyponatremia, Hodgkin´s Lymphoma.
- When are University of Cologne's next clinical trial readouts?
- University of Cologne has 10 upcoming primary-completion readouts tracked here; the soonest is “HD21 for Advanced Stages”, expected around 2022-12.